SPONSOR
Biogen
Total Trials
4
Recruiting
4
Phases
Phase 4, Phase 3
Conditions studied: Amyotrophic Lateral SclerosisFriedreich AtaxiaImmunoglobulin A Nephropathy (IgAN)Primary Membranous Nephropathy
Biogen is a clinical research sponsor with 4 registered studies on ClinicalTrials.gov, of which 4 are actively recruiting participants. Research covers conditions including Amyotrophic Lateral Sclerosis, Friedreich Ataxia, Immunoglobulin A Nephropathy (IgAN), Primary Membranous Nephropathy.
The trial portfolio spans Phase 4, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Biogen
How many clinical trials has Biogen sponsored?
ClinicalMetric currently tracks 4 clinical trials sponsored by Biogen, of which 4 are actively recruiting participants. These trials cover conditions including Amyotrophic Lateral Sclerosis, Friedreich Ataxia, Immunoglobulin A Nephropathy (IgAN). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Biogen research focus on?
Biogen clinical trials span Amyotrophic Lateral Sclerosis, Friedreich Ataxia, Immunoglobulin A Nephropathy (IgAN), Primary Membranous Nephropathy. The research pipeline includes Phase 4, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Biogen clinical trial?
To participate in a Biogen trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Biogen trials with current recruitment status updated daily.
Clinical Trials by Biogen
NCT07223723 Phase 4
Recruiting
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
NCT06623890
Recruiting
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
Friedreich Ataxia
NCT06935357 Phase 3
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
NCT06962800 Phase 3
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
Primary Membranous Nephropathy
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology